$AIP

RAZA SAIYED ATIQ sold $779K of AIP (indirect holdings)

RAZA SAIYED ATIQ sold 20,839 indirectly-held shares of Arteris, Inc. (AIP) at an average of $37.39 ($37.13–$38.46, $0.78M total) across 3 trades on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAZA SAIYED ATIQ
Published Jun 4, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Bearish
medium confidence
Mentioned
$AIP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPBearishLow
01

Why it matters

The director's sale reduces his ownership but is pre‑arranged, so market reaction may be muted.

02

Market read

A modest insider sell that may cause slight short‑term price pressure but is unlikely to drive broader market moves.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the director to free cash.

Relevance 4/10Novelty 5/10Timing: post‑market filing today

Background

Arteris, Inc. (AIP) is a micro‑cap semiconductor IP provider listed on Nasdaq. The filing is a standard Form 4 disclosure of an insider transaction.

Company-level read

Ticker impact

$AIPBearishMedium confidence
Context

Director Raza Saied Atiq sold 20,839 shares for $779K via a 10b5-1 plan, reducing his stake to 140,000 shares.

Expected impact

likely slight downward pressure as the market prices the director's sell.

Evidence & confidence

A $779K sale by a director is material for a micro‑cap, but the amount is modest and the transaction was pre‑arranged, limiting immediate impact.

Market effects

Minimal; insider activity does not affect the broader semiconductor design sector.

None; the filing is company‑specific.

Low; no broader market impact.

Counterpoint

The sale could be purely liquidity‑driven under a 10b5‑1 plan, not a negative signal.

Key entities

  • Arteris, Inc.

    Issuer of the Form 4 filing.

  • Raza Saied Atiq

    Director and seller of the shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to